Skip to main content
SpringerLink
Log in

PSA and obesity among men with localized prostate cancer: results of the ANDROCAN study

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

PSA is known to be lowered in obese patients. There is a lack of data regarding patients with prostate cancer. Our objective was to prospectively assess the relationship PSA concentration, PSA mass and BMI in a cohort of patients with localized prostate cancer.

Methods

A prospective, multicenter cohort study was conducted including patients undergoing radical prostatectomy. Clinical and biological data were collected for each patient before surgery.

Results

A total of 1343 patients were analyzed. Mean age was 64.0 years. Mean weight was 82.2 kg and mean BMI was 26.8 kg/m2. Mean PSA concentration was 8.7 ng/mL and mean PSA mass 29.3 ng.

On univariate analysis, an association was found between PSA mass and either BMI, weight and waist circumference. No association was found between PSA concentration and each weight parameters.

On multivariate analysis, obesity was not an independent predictor of PSA concentration (p = 0.73). Independent predictors of PSA concentration were cardiovascular disease (negative association, p = 0.034), predominant Gleason 4 (positive association, p < 0.001) and pT3a (positive association, p < 0.001).

BMI was an independent predictor of PSA mass (positive association, p = 0.009). PSA mass was negatively associated with TT (p = 0.015) and cardiovascular disease (p = 0.003), and positively associated with BT (p = 0.032), Gleason grade ≥ 4 + 3 (p < 0.001) and pT3a (p < 0.001).

Conclusion

In this prospective study of patients with localized prostate cancer, higher BMI was associated with higher PSA mass but not with higher PSA concentration. Screening obese patients with a specific PSA method does not appear to be critical.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262

    Article  PubMed  Google Scholar 

  2. Hugosson J, Carlsson S, Aus G et al (2010) Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11(8):725–732. https://doi.org/10.1016/S1470-2045(10)70146-7

    Article  PubMed  PubMed Central  Google Scholar 

  3. Tsodikov A, Gulati R, Heijnsdijk EAM et al (2017) Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med 167(7):449–455. https://doi.org/10.7326/M16-2586

    Article  PubMed  PubMed Central  Google Scholar 

  4. Swinburn BA, Sacks G, Hall KD et al (2011) The global obesity pandemic: shaped by global drivers and local environments. Lancet Lond Engl 378(9793):804–814. https://doi.org/10.1016/S0140-6736(11)60813-1

    Article  Google Scholar 

  5. Bañez LL, Hamilton RJ, Partin AW et al (2007) Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298(19):2275–2280. https://doi.org/10.1001/jama.298.19.2275

    Article  PubMed  Google Scholar 

  6. Klaassen Z, Howard LE, Moreira DM, Andriole GL, Terris MK, Freedland SJ (2017) Association of obesity-related hemodilution of prostate-specific antigen, dihydrotestosterone, and testosterone. Prostate 77(5):466–470. https://doi.org/10.1002/pros.23285

    Article  CAS  PubMed  Google Scholar 

  7. Wright JL, Lin DW, Stanford JL (2011) The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate 71(15):1631–1637. https://doi.org/10.1002/pros.21380

    Article  PubMed  PubMed Central  Google Scholar 

  8. Bonn SE, Sjölander A, Tillander A, Wiklund F, Grönberg H, Bälter K (2016) Body mass index in relation to serum prostate-specific antigen levels and prostate cancer risk. Int J Cancer 139(1):50–57. https://doi.org/10.1002/ijc.30052

    Article  CAS  PubMed  Google Scholar 

  9. Aref AT, Vincent AD, O’Callaghan ME et al (2018) The inverse relationship between prostate specific antigen (PSA) and obesity. Endocr Relat Cancer 25(11):933–941. https://doi.org/10.1530/ERC-17-0438

    Article  CAS  PubMed  Google Scholar 

  10. Kelly DM, Jones TH (2015) Testosterone and obesity. Obes Rev Off J Int Assoc Study Obes 16(7):581–606. https://doi.org/10.1111/obr.12282

    Article  CAS  Google Scholar 

  11. Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 71(4):618–629. https://doi.org/10.1016/j.eururo.2016.08.003

    Article  PubMed  Google Scholar 

  12. Sanda MG, Cadeddu JA, Kirkby E et al (2018) Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options. J Urol 199(4):990–997. https://doi.org/10.1016/j.juro.2018.01.002

    Article  PubMed  Google Scholar 

  13. Bhasin S, Brito JP, Cunningham GR et al (2018) Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103(5):1715–1744. https://doi.org/10.1210/jc.2018-00229

    Article  PubMed  Google Scholar 

  14. Giton F, Trabado S, Maione L et al (2015) Sex steroids, precursors, and metabolite deficiencies in men with isolated hypogonadotropic hypogonadism and panhypopituitarism: a GCMS-based comparative study. J Clin Endocrinol Metab 100(2):E292-296. https://doi.org/10.1210/jc.2014-2658

    Article  CAS  PubMed  Google Scholar 

  15. Epstein JI, Egevad L, Amin MB et al (2016) The 2014 International society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244–252. https://doi.org/10.1097/PAS.0000000000000530

    Article  PubMed  Google Scholar 

  16. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-Part B: prostate and bladder tumours. Eur Urol 70(1):106–119. https://doi.org/10.1016/j.eururo.2016.02.028

    Article  PubMed  Google Scholar 

  17. Neuzillet Y, Raynaud J-P, Dreyfus J-F et al (2019) Aggressiveness of localized prostate cancer: the key value of testosterone deficiency evaluated by both total and bioavailable testosterone: androcan study results. Horm Cancer 10(1):36–44. https://doi.org/10.1007/s12672-018-0351-8

    Article  CAS  PubMed  Google Scholar 

  18. Obesity. Accessed November 14, 2020. https://www.who.int/westernpacific/health-topics/obesity

  19. TNM Classification of malignant tumours, 8th Edition|Wiley. Wiley.com. Accessed November 14, 2020. https://www.wiley.com/en-us/TNM+Classification+of+Malignant+Tumours%2C+8th+Edition-p-9781119263579

  20. Kolb R, Sutterwala FS, Zhang W (2016) Obesity and cancer: inflammation bridges the two. Curr Opin Pharmacol 29:77–89. https://doi.org/10.1016/j.coph.2016.07.005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study could have been done through a grant of the Foch Foundation, a non-profit institution, and a grant of the French Ministry of Health/DGOS/CRC3F.

Author information

Authors and Affiliations

  1. Department of Urology, Université de Versailles-Saint-Quentin-en-Yvelines, Hôpital Foch, Service d’urologie40 rue Worth, 92150, Suresnes, France

    Matthias E. Meunier, Yann Neuzillet, Thierry Lebret & Henry Botto

  2. University of Versailles-Saint-Quentin-en-Yvelines, Versailles, France

    Matthias E. Meunier, Yann Neuzillet & Thierry Lebret

  3. Department of Clinical Research and Innovations, University of Versailles-Saint-Quentin-en-Yvelines, Versailles, France

    Jean-François Dreyfus

  4. Department of Urology, Hôpital Louis Pasteur, Colmar, France

    Marc Schneider

  5. Department of Urology, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France

    Morgan Rouprêt

  6. Department of Urology, Institut Mutualiste Montsouris, Paris-Descartes University, Paris, France

    Xavier Cathelineau

  7. Sorbonne University, Paris, France

    Jean-Pierre Raynaud

Authors
  1. Matthias E. Meunier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yann Neuzillet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-François Dreyfus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marc Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Morgan Rouprêt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xavier Cathelineau
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jean-Pierre Raynaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Thierry Lebret
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Henry Botto
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MEM: data collection and analysis, manuscript writing and editing. YN: protocol and project development, data management, data analysis, manuscript editing. J-FD: data analysis and manuscript editing. MS: protocol and project development. mr: protocol and project development. XC: protocol and project development. J-PR: protocol and project development. TL: protocol and project development. HB: protocol and project development, data management and manuscript editing.

Corresponding author

Correspondence to Matthias E. Meunier.

Ethics declarations

Conflict of interest

None, from the corresponding author or from any of the co-authors.

Research involving human participants

The institutional review boards of all centers approved the study protocol. The trial was registered (NCT02235142) and conducted in accordance with the Declaration of Helsinki.

Informed consent

Written informed consent was obtained from all patients.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meunier, M.E., Neuzillet, Y., Dreyfus, JF. et al. PSA and obesity among men with localized prostate cancer: results of the ANDROCAN study. World J Urol 39, 2945–2951 (2021). https://doi.org/10.1007/s00345-020-03557-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-020-03557-6

Keywords

Search

Navigation